Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
News|Articles|November 20, 2014
Vetter Opens New Office in Singapore to Support Growing Asian Market
Author(s)Pharmaceutical Technology Editors
CDMO Vetter has opened a new representative office in Singapore in response to growing market demand in Asia.
Advertisement
CDMO Vetter, a specialist in aseptic fill and finish of injection systems for the bio/pharmaceutical industry, has opened a new representative office in Singapore in response to growing market demand in Asia. The announcement was made at a ceremony attended by members of local government agencies, a number of executives of pharmaceutical/biotech companies in the Asian region, and Vetter executives.
The new office, headed by Chervee Ho, director, Key Account Management, Asia Pacific, will enable the company to better serve the Asian market, which was previously handled by Vetter’s German-based departments.
Source:
Advertisement
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA/CMS Gene Editing Guidance Shifts Evidence to CMC Teams
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
5